 Connection
Scott Berkowitz to Clinical Trials as Topic
This is a "connection" page, showing publications Scott Berkowitz has written about Clinical Trials as Topic.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.183 |
|
|
|
-
Verheugt FW, Clemmensen P, Mehran R, Agewall S, Pocock SJ, Goldstein S, Torp-Pedersen C, Simoons ML, Borer JS, Khder YM, Burton P, Deliargyris E, McMurray JJ, Berkowitz SD, Stough WG, Zannad F. Antithrombotic outcome trials in acute coronary syndromes: seeking the optimal balance between safety and efficacy. Eur Heart J. 2013 Jun; 34(22):1621-9.
Score: 0.077
-
Kubitza D, Berkowitz SD, Misselwitz F. Evidence-Based Development and Rationale for Once-Daily Rivaroxaban Dosing Regimens Across Multiple Indications. Clin Appl Thromb Hemost. 2016 Jul; 22(5):412-22.
Score: 0.024
-
Berkowitz SD. Treatment of established deep vein thrombosis: a review of the therapeutic armamentarium. Orthopedics. 1995 Jul; 18 Suppl:18-20.
Score: 0.023
-
Fordyce CB, Roe MT, Ahmad T, Libby P, Borer JS, Hiatt WR, Bristow MR, Packer M, Wasserman SM, Braunstein N, Pitt B, DeMets DL, Cooper-Arnold K, Armstrong PW, Berkowitz SD, Scott R, Prats J, Galis ZS, Stockbridge N, Peterson ED, Califf RM. Cardiovascular drug development: is it dead or just hibernating? J Am Coll Cardiol. 2015 Apr 21; 65(15):1567-82.
Score: 0.023
-
Zannad F, Stough WG, Regnault V, Gheorghiade M, Deliargyris E, Gibson CM, Agewall S, Berkowitz SD, Burton P, Calvo G, Goldstein S, Verheugt FW, Koglin J, O'Connor CM. Is thrombosis a contributor to heart failure pathophysiology? Possible mechanisms, therapeutic opportunities, and clinical investigation challenges. Int J Cardiol. 2013 Sep 01; 167(5):1772-82.
Score: 0.019
-
Misselwitz F, Berkowitz SD, Perzborn E. The discovery and development of rivaroxaban. Ann N Y Acad Sci. 2011 Mar; 1222:64-75.
Score: 0.017
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|